Hepion Pharmaceuticals ( (HEPA) ) has released a notification of late filing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hepion Pharmaceuticals, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for the delay is the ongoing process of compiling necessary information, which could not be completed without unreasonable effort and expense. The company anticipates filing the report within a 5-day extension period. Financially, significant changes are expected, with notable decreases in research and development expenses due to reduced clinical trial costs and headcount. General and administrative expenses also saw a reduction, primarily due to decreased employee stock compensation and salaries. Hepion Pharmaceuticals is committed to maintaining compliance, as evidenced by the signature of Interim CEO John Brancaccio on the notification.
More about Hepion Pharmaceuticals
Average Trading Volume: 4,889,603
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.48M
For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.